Market Cap 1.76B
Revenue (ttm) 0.00
Net Income (ttm) -846.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.91
Volume 1,281,500
Avg Vol 2,315,744
Day's Range N/A - N/A
Shares Out 105.79M
Stochastic %K 53%
Beta 1.03
Analysts Strong Sell
Price Target $44.62

Company Profile

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 tha...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
Damian23
Damian23 Oct. 25 at 4:34 PM
$BHVN Flagship drug: Troriluzole (BHV‑4157) for Spinocerebellar Ataxia (SCA); first‑in‑class therapy with Q4 2025 FDA decision expected.​ Pipeline overview: 5 programs total; most advanced 2 are Troriluzole (≈85% approval likelihood) and BHV‑7000 (≈65%).​ Patient population (TAM): 15,000–20,000 SCA patients in U.S.; ≈35,000–40,000 globally eligible for Orphan use.​ Serviceable (SAM): About 60% are diagnosed and accessible through neurology centers → ≈9,000 U.S. and ≈20,000 global patients. Orphan‑drug pricing: Based on peer comparables (Skyclarys ≈ $370K, Spinraza ≈ $350K, Relyvrio ≈ $158K), Troriluzole likely around $200,000/year.​ Market penetration: 50% in the U.S., 30% ex‑U.S. within 5 years; net treated ≈4,500 U.S. and 6,000 ex‑U.S. patients by 2029. Peak revenue (U.S.): 4,500 × $200,000 = $900 million. Peak global revenue: 6,000 × $160,000 (average discounted ex‑U.S. price) = $960 million.
2 · Reply
RandomInvestor777
RandomInvestor777 Oct. 21 at 8:59 PM
$BHVN risky short/long imo
0 · Reply
trading_insight
trading_insight Oct. 21 at 3:21 PM
$ARCT and $BHVN on the move
0 · Reply
FloatTrip
FloatTrip Oct. 21 at 3:05 AM
$BHVN Showing some Strength today, ..it's a Bull!
0 · Reply
HamBoneXoXo
HamBoneXoXo Oct. 20 at 5:18 PM
$BHVN I find it wise to come to mist biotech binary events after and not before. This is not about bhvn but in general. Unless leveraged the risk is too consequential to be exposed naked to an fda binary.
0 · Reply
Ccg_
Ccg_ Oct. 20 at 12:57 PM
$BHVN she wants to run!
0 · Reply
Smellmahass
Smellmahass Oct. 17 at 11:16 PM
$BHVN I havent done proper DD yet but Im assuming approval here is not confident as comparator is unreliable?
1 · Reply
MaxDanger
MaxDanger Oct. 16 at 1:33 AM
$BHVN It’s surprising that the company hasn’t assembled a commercial team, especially with regulatory approval weeks away. Additionally, their lack of urgency in raising capital is puzzling. According to the latest earnings call, their cash runway is limited to just a few weeks. The most plausible explanation is that management is positioning the company for a full sale or divesting this specific asset upon approval and using that cash to fund their pipeline.
8 · Reply
QuantInsider
QuantInsider Oct. 15 at 5:50 PM
$BHVN popped 4.7% today but no news driving it Options flow isn't backing the move either All I see is a small put sweep with 493 Oct 17 $10 puts for about $12K, 42% OTM and 426% IV No bullish call action to confirm the rally Feels low conviction to me I'd wait for more solid signs before jumping in
0 · Reply
NatureboyRay
NatureboyRay Oct. 15 at 4:02 PM
$BHVN if they get an offer for 10BN these guys need to take it.
1 · Reply
Latest News on BHVN
Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 3 months ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.


Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 3 months ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.


Why Is Biohaven Stock Falling On Thursday?

May 15, 2025, 1:22 PM EDT - 5 months ago

Why Is Biohaven Stock Falling On Thursday?


Damian23
Damian23 Oct. 25 at 4:34 PM
$BHVN Flagship drug: Troriluzole (BHV‑4157) for Spinocerebellar Ataxia (SCA); first‑in‑class therapy with Q4 2025 FDA decision expected.​ Pipeline overview: 5 programs total; most advanced 2 are Troriluzole (≈85% approval likelihood) and BHV‑7000 (≈65%).​ Patient population (TAM): 15,000–20,000 SCA patients in U.S.; ≈35,000–40,000 globally eligible for Orphan use.​ Serviceable (SAM): About 60% are diagnosed and accessible through neurology centers → ≈9,000 U.S. and ≈20,000 global patients. Orphan‑drug pricing: Based on peer comparables (Skyclarys ≈ $370K, Spinraza ≈ $350K, Relyvrio ≈ $158K), Troriluzole likely around $200,000/year.​ Market penetration: 50% in the U.S., 30% ex‑U.S. within 5 years; net treated ≈4,500 U.S. and 6,000 ex‑U.S. patients by 2029. Peak revenue (U.S.): 4,500 × $200,000 = $900 million. Peak global revenue: 6,000 × $160,000 (average discounted ex‑U.S. price) = $960 million.
2 · Reply
RandomInvestor777
RandomInvestor777 Oct. 21 at 8:59 PM
$BHVN risky short/long imo
0 · Reply
trading_insight
trading_insight Oct. 21 at 3:21 PM
$ARCT and $BHVN on the move
0 · Reply
FloatTrip
FloatTrip Oct. 21 at 3:05 AM
$BHVN Showing some Strength today, ..it's a Bull!
0 · Reply
HamBoneXoXo
HamBoneXoXo Oct. 20 at 5:18 PM
$BHVN I find it wise to come to mist biotech binary events after and not before. This is not about bhvn but in general. Unless leveraged the risk is too consequential to be exposed naked to an fda binary.
0 · Reply
Ccg_
Ccg_ Oct. 20 at 12:57 PM
$BHVN she wants to run!
0 · Reply
Smellmahass
Smellmahass Oct. 17 at 11:16 PM
$BHVN I havent done proper DD yet but Im assuming approval here is not confident as comparator is unreliable?
1 · Reply
MaxDanger
MaxDanger Oct. 16 at 1:33 AM
$BHVN It’s surprising that the company hasn’t assembled a commercial team, especially with regulatory approval weeks away. Additionally, their lack of urgency in raising capital is puzzling. According to the latest earnings call, their cash runway is limited to just a few weeks. The most plausible explanation is that management is positioning the company for a full sale or divesting this specific asset upon approval and using that cash to fund their pipeline.
8 · Reply
QuantInsider
QuantInsider Oct. 15 at 5:50 PM
$BHVN popped 4.7% today but no news driving it Options flow isn't backing the move either All I see is a small put sweep with 493 Oct 17 $10 puts for about $12K, 42% OTM and 426% IV No bullish call action to confirm the rally Feels low conviction to me I'd wait for more solid signs before jumping in
0 · Reply
NatureboyRay
NatureboyRay Oct. 15 at 4:02 PM
$BHVN if they get an offer for 10BN these guys need to take it.
1 · Reply
Ccg_
Ccg_ Oct. 15 at 3:58 PM
$BHVN what is that candle?!?
1 · Reply
TopazFrenzy
TopazFrenzy Oct. 15 at 1:45 PM
$BHVN Takeover target
1 · Reply
Smellmahass
Smellmahass Oct. 15 at 12:46 AM
$BHVN Has anyone find if this can be traded using a straddle? I suspect this will pop more than 50 percent if approved or drop 50 percent.
2 · Reply
sellthedip1
sellthedip1 Oct. 15 at 12:37 AM
0 · Reply
Dragonfire89
Dragonfire89 Oct. 14 at 10:34 PM
$BHVN Good video on BHVN. https://youtube.com/watch?v=8AzObPqKsHk&si=V3gMHOzxU5ZIZqBG
0 · Reply
MidnightMadness
MidnightMadness Oct. 14 at 8:52 PM
$BHVN Also the PDUFA date was set for Aug 15, 2025. The FDA extended the date by three months (4Q2025) to allow for a full review of new data submissions, though no new major concerns were raised. So by my watch....we will get a decision on/before Nov 15 or a bit later due to govt shut down.
1 · Reply
MidnightMadness
MidnightMadness Oct. 14 at 8:40 PM
$BHVN FWIW: In previous govt shut downs - the FDA missed user action fee dates and later extended them by the length of the shutdown. So wouldn't be out of the ordinary to see a small delay for products being reviewed.
0 · Reply
buckiii2
buckiii2 Oct. 14 at 7:24 PM
0 · Reply
MidnightMadness
MidnightMadness Oct. 14 at 5:22 PM
$BHVN Potential for delay with Fed shut down? FDA is on a skeleton crew.
1 · Reply
Gurujoe
Gurujoe Oct. 14 at 3:04 PM
$BHVN Look for an imminent announcement for the BHVN lead drug troriluzole, the 3-month date is October 14th. Drug has priority review, fast track and orphan drug in which advisory committee review was not required a further positive. Based on historical reviews of drugs with all three designation (fast track, orphan and priority), 80%-90% have obtained approval. https://ir.biohaven.com/news-releases/news-release-details/fda-extends-pdufa-date-biohavens-troriluzole-nda-rare-disease
1 · Reply
Bbboston
Bbboston Oct. 14 at 3:51 AM
$BHVN For those who have been invested in this; Suppose they gets approval from FDA. Where could this go? MC of $1.6 billion? how much money do they expect to make With a rare disease drug? I have a very small position and like to find reasons to buy more. Understand they have a good history and a pretty impressive pipeline but entry at this level seems like an expensive entry!!
3 · Reply
TaxLossMaster
TaxLossMaster Oct. 13 at 4:14 PM
$BHVN selling the 11/21 $30C covered against shares seems like a great value with the VIX inflated. Still holding this risky biotech play $15.01 AVG
0 · Reply